Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aterovax SA

This article was originally published in Start Up

Executive Summary

Current treatments for atherosclerosis use markers and therapeutic targets that are consequences of the disease. Aterovax SA is attempting a more direct route. By basing its research and pipeline on sPLA2, a family of secreted phospholipases that are mediators in the inflammatory process involved in atherosclerosis, it hopes to create products that are either predictive of cardiovascular disease rather than simply diagnostic, or that can stop the development of unstable atherosclerotic plaques.

You may also be interested in...



Start-Up Previews (12/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Bringing New Blood to the Anemia Market," features profiles of Akebia, Neumedicines and Palkion. Plus these Start-Ups Across Health Care: Aterovax, Pico-Tesla Magnetic Therapies, SpineAlign Medical, Theraclion, Virdante Pharmaceuticals and Zacharon Pharmaceuticals.

Start-Up Previews (12/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Bringing New Blood to the Anemia Market," features profiles of Akebia, Neumedicines and Palkion. Plus these Start-Ups Across Health Care: Aterovax, Pico-Tesla Magnetic Therapies, SpineAlign Medical, Theraclion, Virdante Pharmaceuticals and Zacharon Pharmaceuticals.

After Statins, What Next?

As statins go generic, a host of companies are hunting out new treatments for cholesterol control. They're not put off by recent setbacks, given the huge remaining unmet need and commercial opportunity. Many new companies are still trying to lower LDL and/or raise HDL, but anti-inflammatory approaches are increasingly popular too, as scientists better understand the nature and process of plaque formation.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC091708

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel